246 related articles for article (PubMed ID: 36209205)
1. Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK.
Ge C; Tan J; Dai X; Kuang Q; Zhong S; Lai L; Yi C; Sun Y; Luo J; Zhang C; Zhu L; Wang B; Xu M
Nat Commun; 2022 Oct; 13(1):5945. PubMed ID: 36209205
[TBL] [Abstract][Full Text] [Related]
2. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.
Lin HP; Ho HM; Chang CW; Yeh SD; Su YW; Tan TH; Lin WJ
FASEB J; 2019 Dec; 33(12):14653-14667. PubMed ID: 31693867
[TBL] [Abstract][Full Text] [Related]
3. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
4. JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration.
Li JP; Fu YN; Chen YR; Tan TH
J Biol Chem; 2010 Feb; 285(8):5472-8. PubMed ID: 20018849
[TBL] [Abstract][Full Text] [Related]
5. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
6. Scaffold Role of DUSP22 in ASK1-MKK7-JNK Signaling Pathway.
Ju A; Cho YC; Kim BR; Park SG; Kim JH; Kim K; Lee J; Park BC; Cho S
PLoS One; 2016; 11(10):e0164259. PubMed ID: 27711255
[TBL] [Abstract][Full Text] [Related]
7. DUSP22 suppresses tumor progression by directly dephosphorylating AKT in non-small cell lung cancer.
Chen J; Kang G; Lei W; Li J; Wang H; Bi Y; Zhang W; Zhang L; Chai L; Wang P; Li X
Mol Carcinog; 2024 Feb; 63(2):314-325. PubMed ID: 37937915
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.
Wang S; Yan ZZ; Yang X; An S; Zhang K; Qi Y; Zheng J; Ji YX; Wang PX; Fang C; Zhu XY; Shen LJ; Yan FJ; Bao R; Tian S; She ZG; Tang YD
Hepatology; 2018 Apr; 67(4):1320-1338. PubMed ID: 29077210
[TBL] [Abstract][Full Text] [Related]
10. Lack of FGF21 promotes NASH-HCC transition
Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
[No Abstract] [Full Text] [Related]
11. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
14. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
15. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
16. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
18. TP53INP1 Downregulation Activates a p73-Dependent DUSP10/ERK Signaling Pathway to Promote Metastasis of Hepatocellular Carcinoma.
Ng KY; Chan LH; Chai S; Tong M; Guan XY; Lee NP; Yuan Y; Xie D; Lee TK; Dusetti NJ; Carrier A; Ma S
Cancer Res; 2017 Sep; 77(17):4602-4612. PubMed ID: 28674078
[TBL] [Abstract][Full Text] [Related]
19. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
Michael C; Martínez-Navarro FJ; de Oliveira S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
